BioArctic’s partner Eisai presented results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer’s disease at CTAD conference

BioArctic’s partner Eisai presented the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference, in San Francisco, California and virtually.

The presentation can be viewed on demand via the investors section of the Eisai Co., Ltd. website.